Clinical Trials DEA History 
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
JUNE 29, 2021
Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects had been experiencing PTSD symptoms for an average of 14 years, and 84 percent had a history of developmental trauma. Image via.
Cannabis Law Report
OCTOBER 20, 2021
Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. So, given the history and credibility of the Institute, why did BoA terminate the 10-year banking relationship with SRI?
SpeedWeed
AUGUST 11, 2021
MAPS Makes History. This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We
Veriheal
AUGUST 31, 2020
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Supply chains are disrupted as a result, and consumers grow fearful of buying hemp.
Expert insights. Personalized for you.
262 
Let's personalize your content